UpdateBenzodiazepine dependence: Focus on withdrawal syndromeDépendance aux benzodiazépines : le syndrome de sevrage
Introduction
Although recommendations for benzodiazepine use with prescription suggest that duration be limited to a few weeks, patients are known to take these drugs for months, years, or even decades. In the 1996 Australian National Health Survey, 58% of the 359,300 benzodiazepine users had been taking this medication for at least 6 months and in another study, 84% of 3234 benzodiazepine users identified in a study of 15 general practices were still using them 8 months later [1], [2]. According to different National and European epidemiological surveys, France had the highest annual rate of anxiolytic use, within a range of 12% to 19%. Duration of benzodiazepine use was more than 6 months in 70 to 75% of users and increased with age [3], [4]. Such long-term use occurs in spite of evidence that the benefits of benzodiazepine may decrease with time, while the potential for adverse effects remains. Potential adverse effects include cognitive decline, unwanted sedation, reduced coordination, increases in risk of accidents, as well as psychological and physical dependence (Table 1). Benzodiazepines have long been known to cause amnesia, an effect that is utilised when the drugs are used as premedication before major surgery or for minor surgical procedures. Oral doses of benzodiazepines in the dosage range used for insomnia or anxiety can also cause episodic memory impairment. Acquisition of new information is deficient, partly because of lack of concentration and attention [5]. According to Neutel [6], the overriding factor associated with likelihood of benzodiazepine use was that of previous use. Other factors associated with benzodiazepine use, whether related to the person or the reason for benzodiazepine use, were considerably less important for long-term users. It may be concluded that once benzodiazepine use has started, specific reasons such as poor health pain or chronic diseases become much less important in long-term use than they are in the earlier phases of benzodiazepine use.
In clinical practice, benzodiazepines should be used for acute anxiety management rather than long-term treatment. However, benzodiazepines continue to be frequently prescribed for the initial treatment of panic disorders, as well as other anxiety disorders and chronic insomnia. These medications are undoubtedly drugs associated with problems on attempted reduction in dosage or withdrawal. The discontinuation syndrome can be severe and can prevent the long-term user from ever stopping the medication. In this update on benzodiazepine withdrawal syndrome, we attempted to explain who is vulnerable, why this syndrome exists and how to withdraw from these drugs.
Section snippets
Vulnerable patients to withdrawal symptoms
Particular care should be taken in prescribing benzodiazepines for vulnerable patients such as elderly, pregnant women and the foetus, children, alcohol and drug abuse dependent patients and patients with comorbid psychiatric disorders.
Clinical aspects
The development of tolerance is one of the reasons people become dependent on benzodiazepines and also sets the scene for the withdrawal syndrome. This syndrome is a key sign of benzodiazepine dependence. Withdrawal symptoms occur when there is a decline in the blood or tissue concentration of any dependence-forming substance that an individual has been continuously taking. These symptoms are generally the opposite of the acute effects of the drug, or they may mimic the symptoms for which the
Biological aspects
The pharmacological mechanisms underlying benzodiazepine withdrawal are complex and still not clear. The result of a rapid or abrupt withdrawal of the benzodiazepine is underactivity of inhibitory GABA (γ-aminobutyric acid) functions and a surge in excitatory nervous activity, giving rise to many of the benzodiazepine symptoms.
First, it is well-established that following chronic exposure to benzodiazepines, there are alterations in GABAergic neurotransmission (up/down regulation GABA-a receptor
Clinical management
Why stopping benzodiazepine? Because long-term use of benzodiazepines can give rise to many unwanted effects, including poor memory and cognition, emotional blunting, depression, increasing anxiety, physical symptoms and dependence, with important social and economic consequences. All benzodiazepines can produce these effects whether taken as anti-anxiety drugs or sleeping pills. Several clinical options exist for discontinuing benzodiazepine treatment, including gradual tapering of the current
Conclusions
The socioeconomic costs of the present high level of long-term benzodiazepine use are considerable, although difficult to quantify. These consequences could be minimised if prescriptions for long-term benzodiazepines were decreased. Yet, many doctors continue to prescribe benzodiazepines and patients wishing to withdraw receive little advice or support on how to go about it.
Due to the variability in medications and research designs, it is not possible to assess conditions under which
Conflicts of interest
None.
References (30)
- et al.
Neonatal consequences of benzodiazepines used during the last month of pregnancy
Arch Pediatr
(2005) - et al.
Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence
Drug Alcohol Depend
(2009) GABAa receptor subtypes: any clues to the mechanism of benzodiazepine dependence?
Curr Opin Pharmacol
(2005)- et al.
The blockade of AMPA-kainate and NMDA receptors in the dorsal periaqueductal gray reduces the effects of diazepam withdrawal in rats
Pharmacol Biochem Behav
(2007) - et al.
Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression
Psychoneuroendocrinology
(2004) - Australian Bureau of Statistics. National Health Survey, First Results, Australia, Canberra 1996. Report 4377.0....
- et al.
Benzodiazepine prescribing and withdrawal for 3234 patients in 15 general practices
Fam Pract
(1994) - The ESEMeD/MHEDEA 2000 investigators. Psychotropic drug utilization in Europe: results from the European Study of the...
- et al.
Patterns and correlates of benzodiazepine use in the French general population
Eur J Clin Pharmacol
(2004) The diagnosis and management of benzodiazepine dependence
Curr Opin Psychiatry
(2005)
The epidemiology of long-term benzodiazepine use
Int Rev Psychiatry
Randomized clinical trials of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia
Am J Psychiatry
Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations
Pharmacoepidem Druf Saf
Opioid and benzodiazepine withdrawal syndromes in the paediatric intensive care unit: a review of recent literature
Nurs Crit Care
Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review
Int Care Med
Cited by (48)
Discriminative stimulus and reinforcing effects of diclazepam in rodents
2024, Pharmacology Biochemistry and BehaviorBehavioral Health Emergencies
2023, Physician Assistant ClinicsOutcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants
2022, Drug and Alcohol DependenceCitation Excerpt :The evidence of BZD tapering in high dose BZD users is limited; therefore, abstinence rates after flumazenil treatment compared to slow BZD tapering should be explored. Although this was a small study, unlike BZD tapering, which is done over months to years (Authier et al., 2009; Voshaar et al., 2006), flumazenil offered a rapid detoxification from BZDs with success rates of abstinence at three-months ranging from 46.2 % to 61.5 %. Data also suggests that flumazenil may manage symptoms of withdrawal and cravings after discontinuation, with many participants only reporting low-moderate withdrawal symptoms and low craving scores at follow-ups after discontinuation.
A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept
2022, Drug and Alcohol DependenceCitation Excerpt :Currently, there are multiple methods suggested in the literature to taper BZDs when cessation is indicated. These include abrupt discontinuation, 25% weekly dose reduction, reduction of one-eighth to one-tenth of daily dose each fortnight, and symptom guided withdrawal, all of which can occur over four-weeks to a year or more (Authier et al., 2009; Voshaar et al., 2006) with or without psychological interventions (Lader et al., 2009). However, even with a slow dose taper, some patients report withdrawal symptoms including anxiety, agitation and restlessness, mood swings, insomnia, impaired memory, nausea and vomiting, tachycardia, and in severe cases, seizures (Mehdi, 2012; Ashton, 2002).
Base and catalyst-free synthesis of nitrobenzodiazepines via a cascade N-nitroallylation-intramolecular aza-Michael addition involving o-phenylenediamines and nitroallylic acetates
2019, TetrahedronCitation Excerpt :The biological significance of benzodiazepine skeleton also prompted development of different synthetic routes from various precursors. These include reaction of o-phenylenediamine with different bielectrophiles [6], one pot conversion of nitroarenes using bimetallic nanoparticles [7], Au(I)-NHC-catalyzed synthesis from N-substituted o-phenylenediamines and terminal alkynes [8] etc. [9] Owing to the importance of nitro group in biologically active compounds [10], and particularly nitrobenzodiazepines (NBDZs) as hypnotic and sedative drugs [11], synthesis of novel NBDZs, in which the nitro group is attached to the 7-membered dinitrogen heterocycle rather than to the aromatic ring, via one pot cascade reactions from readily available starting materials appeared an attractive objective. While one of the substrates for the synthesis of the NBDZs appeared to be 1,4-binucleophilic o-phenylenediamine, a 1,3-bielectrophilic nitroalkene derivative emerged as the other substrate.
Retrospective study of the assessment and management of benzodiazepine withdrawal syndrome in hospital between 2000 and 2015
2017, Annales Pharmaceutiques Francaises